Solid Biosciences reports positive interim Phase 1/2 SGT-003 Duchenne data

with robust microdystrophin expression

INSPIRE DUCHENNE Phase 1/2 interim results indicate an encouraging overall safety profile for SGT-003 treatment.

Data show cardiac function improvements and favorable biomarker changes consistent with microdystrophin expression in treated patients.

Company plans additional FDA meetings to discuss a potential accelerated approval pathway for SGT-003

https://finviz.com/quote.ashx?t=SLDB&p=d